Which treatment option is safe for pregnant women at risk of DVT?

Low molecular weight heparin (LMWH) is considered a safe treatment option for pregnant women at risk of deep vein thrombosis (DVT). This is primarily because LMWH has a better safety profile in pregnancy compared to other anticoagulants. It does not cross the placenta, which minimizes the risk of harm to the developing fetus. Additionally, LMWH is effective in preventing and treating thromboembolic events, making it a suitable choice during pregnancy when managing DVT risk.

In contrast, direct oral anticoagulants and warfarin are generally avoided in pregnant patients. Warfarin, for instance, is known to cross the placenta and can cause fetal teratogenic effects, particularly in the first trimester. Direct oral anticoagulants also lack sufficient safety data during pregnancy, leading to their recommendation against use in this population. Unfractionated heparin, while also safe and sometimes used in pregnancy, is more often reserved for specific patient populations or situations due to the need for more frequent monitoring and adjustments. Therefore, LMWH is the preferred treatment option for pregnant women at risk of DVT, balancing efficacy with safety for both the mother and the fetus.